Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Franks

Showing results (221-230 of 287) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2M E Gore, E Galligioni, C W Keen, et al.
Plos One|March 20, 2010
Record dynamics in antsThomas O Richardson, Elva J H Robinson, Kim Christensen, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicityK G Park, S D Heys, J B Murray, et al.
Cancer Research|August 1, 1975
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed miceE J Stanbredge, L R Boulger, C R Franks, et al.
British Journal of Cancer|December 1, 1992
Interleukin 2 therapy in cancer: identification of respondersJ Broom, S D Heys, P H Whiting, et al.
Anticancer Research|May 1, 1992
Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patientsS S Ubhi, J Hollingworth, T Horsburgh, et al.
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
European Cytokine Network|October 1, 1990
TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2M Favrot, V Combaret, J Y Blay, et al.
Pageof 29

Showing results (221-230 of 287) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2M E Gore, E Galligioni, C W Keen, et al.
Plos One|March 20, 2010
Record dynamics in antsThomas O Richardson, Elva J H Robinson, Kim Christensen, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Cancer Biotherapy|January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II StudyJ Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicityK G Park, S D Heys, J B Murray, et al.
Cancer Research|August 1, 1975
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed miceE J Stanbredge, L R Boulger, C R Franks, et al.
British Journal of Cancer|December 1, 1992
Interleukin 2 therapy in cancer: identification of respondersJ Broom, S D Heys, P H Whiting, et al.
Anticancer Research|May 1, 1992
Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patientsS S Ubhi, J Hollingworth, T Horsburgh, et al.
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
European Cytokine Network|October 1, 1990
TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2M Favrot, V Combaret, J Y Blay, et al.
Pageof 29